

Haematologica
HAEMATOL/2017/164103
Version 4

Incidence and management of toxicity associated with ibrutinib and
idelalisib: a practical approach

Iris de Weerd, Suzanne M Koopmans, Arnon P Kater, and Michel van
Gelder

Disclosures: IdW and SMK received honoraria from Gilead. MvG received honoraria from Janssen, Gilead, Roche and Abbvie. APK received honoraria and research funding from Janssen, Gilead, Abbvie and Genentech.

Contributions: All authors (IdW, SMK, APK and MvG) wrote the manuscript, provided intellectual input and approved the final manuscript.